CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Set to Begin Enrolling Brain Cancer Drug Trial Participants
Brain cancer drug developer CNS Pharmaceuticals is finalizing preparations to begin March enrollment of patients in its potentially pivotal Phase 2 trial evaluating its promising lead candidate, Berubicin, for the overall survival improvement of glioblastoma (“GBM”) patients Glioblastomas are a type of brain cancer that have continued to elude effective therapy over the past century of investigation, leaving patients with expectations of approximately 15 months of survivability beyond diagnosis and recurrence after surgical removal A GBM patient in a small Phase 1 Berubicin safety trial 15 years ago has remained cancer-free and stable as of last November, a hint of…